Computer Simulation: Concept and Application in Formulation and Development
Computer Simulation: Concept and Application in Formulation and Development
Before a new drug can be released on the market, it must be formulated to produce
a quality product that is acceptable to both regulatory bodies and patients and can
be manufactured on a large scale.
There are many formulation types depending on the route of administration of the
active drug.
The process of formulation for any of the Pharmaceutical product is generically the
same, beginning with some form of product specification and ending with one or
more formulations that meet the requirements.
Correct choice of additives or excipients is paramount in the provision of efficacy,
stability, and safety.
For instance, the excipients may be chemically or physically incompatible with the
drug or they may exhibit batchwise variability to such an extent that at the
extremes of their specification they may cause failure in achieving the desired drug
release profile.
These include expert and knowledge-based systems for the generation of initial
formulations and processing conditions ab initio; neural computing for modeling
formulation and process data to explore relationships within the data set and
optimize the formulation; and computer simulation for the development of
mathematical models of the interaction between the formulation and the
manufacturing process to predict outcomes.
The idea behind this work is to assist the formulation of products with the added
benefits of consistent decision making, decreased timelines, and cost savings.
EXPERT AND KNOWLEDGE-BASED SYSTEMS
• Forward chaining, which involves the system reasoning from the data and
information gained by consultation with the user to form a hypothesis
• Backward chaining, which involves the system starting with a hypothesis and then
attempting to find data and information to prove or disprove the hypothesis.
The properties of a formulation are determined not only by the ratios in which the
ingredients are combined but also by the processing conditions.
1. neural networks (an attempt to mimic the processing of the human brain);
3. fuzzy logic (an attempt to mimic the ability of the human brain to draw
conclusions and generate responses based on incomplete or imprecise
information).
Like humans, neural networks learn directly from input data.
1. Unsupervised learning, where the network is presented with input data and learns
to recognize patterns in the data, is useful for organizing amounts of data into a
smaller number of clusters.
Simulation is best described as the process of translating a real system into a working
model in order to run experiments.
Computational resources available today, large scale models of the body can be
used to produce realistic simulations.
Computer simulation is the actual running of the program that contains these equations
or algorithms.
Software- BIOSPHERA
IVALA
Software for computer simulation is often customized and based on that developed in
academia. There are not many commercial packages available for pharmaceutical
formulation.
In the current situation, the rapid development of technologies and computer
simulation is an integral part in the field of Pharmacokinetic and Pharmacodynamics
studies.
The success of computer simulation methods depends on the quality of data inputs
available.
The main reason behind the less development of the simulation technique in the field
of medical is that critical part in understanding the aim and objective of the study,
which is the essential part for all experts.
Make a Model
Real System
Model System
Construct
Perform Perform
approximate
Experiments Simulations
theories
The essential goal of biocomputing is that computer simulation is able to model the
whole organism.
B. Physiological modeling
The lumped element model (also called lumped parameter model, or component
model), is a simplified description of the behaviour of spatially distributed physical
systems into a topology consisting of discrete entities that approximate the behaviour of
the distributed system under certain assumptions.
Plasma concentration over time was best described by a two-compartment linear model
and body weight was associated with central volume of distribution.
To predict the system’s behaviour over time, use a relatively small number of
differential equations, between one and ten.
It is also used to estimate both the population parameter values and their statistical
distribution.
The same approach can be taken in reverse by using models to generate synthetic
data, ultimately performing a full clinical trial simulation from fist principles.
PHYSIOLOGICAL MODELING
The model is still based on ordinary equations, but they strive to describe in more
detail about organism and especially the interacting organs.
A consensus workshop developed some time ago, a set of “good practices” that can
serve as guidance to model development, selection and application.
PBPK models can suffer greatly in their predictive power if their parameterization
is inaccurate, poorly specified, or not well tailored to the particular drug.
It is intresting to note that the foremost challenges for the detailed modelling of the
intact organism ( computing time, complexity of interactions, model selection).
ISOLATED TISSUE AND ORGANS
Historically, the organs that are most extensively investigated include Heart and the Liver.
Even though the Kideny and Brain have also been the subjects of mathematical modeling
research.
Many of the computer simulations for Heart and Liver were carried out with Distributed
Blood Tissue Exchange (BTEX) Models.
The model BTEX is used because of the increased level of detail and temporal resolution
certainly makes the good mixing and uniformity hypotheses at the basis of lumped
parameter models less reasonable.
It can be hypothesized that the integration of organ-specific modeling with the
whole organism models would result in improvements for the PBPK approach
through “better” (i.e. more ohysiologically sensible and plausible) models of
individual organs.
The main challenge in doing so is the required shift from lumped to distributed
parameter models.
The physiome describes the physiological dynamics of the normal intact organism
and is built upon information and structure (genome, proteome, and morphome).
CELL, PROTEIN AND GENES
BENEFITS
Many simulations performed with minimum effort.
Assists in determining the accuracy to which the input parameters need to be controlled.
Allows the testing of the system in operating conditions that would be costly, dangerous, or time
consuming to perform.
Computer simulation methods helps in rapid development of dosage forms with cheaper price and
by using less manpower.
The mechanical modeling of the tablet compaction process with finite elements was first
attempted in 1987 and has been refined since.
However, this methodology is based on the assumption that a tablet is a continuum, the
properties of which can be defined by constitutive equations.
It works well for tablet formulations comprising one ingredient but has little relevance
to multicomponent formulations.
The method is currently being evaluated and validated against experimental data,
but initial results indicate that it does capture the characteristics of the
pharmaceutical tableting process.
A prerequisite of tablet compaction is the initial filling of the tablet die with
powder.
Powder packing is one process that has received a great deal of attention, and
commercial software for simulating this process is available (Macro Pac,
Intelligensys Ltd., UK).
Recently this simulation has been made available as MacroCrack from Intelligensys
Ltd., UK.
A computer simulation of crack propagation in a
tablet film coating containing one population of an
inclusion
CONCLUSION
The next generation of formulators in the pharmaceutical industry are likely to find
themselves using all of the above techniques routinely and to an increasing extent.
Several pharmaceutical companies have already implemented some of them and made
them available to formulators either as stand-alone programs or linked via an intranet.
However, the largest benefit in the future will undoubtedly arise from the seamless
integration of all of the techniques into a common decision support system allowing the
in silico generation of formulated products ab initio with the added benefits of
consistency, decreased timelines, and cost savings.
REFERENCES